Post by PharmaShots

BioCryst Pharmaceuticals, Inc. licenses European rights to navenibart to an Irish affiliate of Neopharmed Gentili S.P.A. in a ~$345M deal to advance a P-III long-acting kallikrein inhibitor for hereditary angioedema  Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #biocryst #neopharmedgentili #navenibart #licensingdeal #hereditaryangioedema #plasmakallikreininhibitor #phaseiii #pharma https://lnkd.in/gxYWpZ7D